Calidi Biotherapeutics Inc. announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. The company's presentation will focus on its proprietary RedTail platform, an engineered enveloped oncolytic virus technology designed for systemic administration to target metastatic cancer sites. The RedTail platform represents a significant advancement in immuno-oncology by addressing one of the major challenges in virotherapy: immune system clearance of therapeutic viruses before they reach tumor sites.
This technology is engineered to shield the virus from immune detection, allowing it to effectively reach distant metastatic locations, induce tumor lysis, and deliver therapeutic genetic medicines directly to cancer cells throughout the body. Calidi's lead candidate from the RedTail platform is currently in IND-enabling studies targeting non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. The company's approach could potentially transform cancer treatment by enabling systemic delivery of oncolytic viruses, moving beyond the limitations of localized administration that have constrained previous virotherapy approaches.
The availability of an on-demand presentation starting September 5 at 7 a.m. ET provides investors and the medical community with early access to detailed information about Calidi's technology and development progress. This presentation comes at a critical time as the company advances its clinical-stage programs, including both systemic and intratumoral administration approaches for various cancer indications. For investors seeking additional information, the company maintains a newsroom at https://ibn.fm/CLDI where updates and developments are regularly posted.
The conference presentation represents an important opportunity for Calidi to demonstrate the potential of its platform technology to address significant challenges in metastatic cancer treatment and position itself within the competitive immuno-oncology landscape. The company's focus on systemic administration represents a departure from traditional virotherapy approaches that have been limited by immune clearance mechanisms. By engineering viruses that can evade immune detection, Calidi's technology could enable more effective treatment of metastatic cancers that have proven difficult to target with conventional therapies.
This development matters because metastatic cancer remains a leading cause of cancer-related deaths worldwide, with current treatment options often providing limited efficacy and significant side effects. The ability to systemically deliver oncolytic viruses could represent a paradigm shift in cancer treatment, potentially offering more targeted and effective therapies for patients with advanced disease. Calidi's progress in advancing its RedTail platform through IND-enabling studies suggests the technology is moving closer to clinical testing, which could provide important validation of its therapeutic potential.
The investment community's interest in Calidi's presentation reflects growing recognition of the potential for engineered oncolytic viruses to address unmet needs in oncology. As the company prepares to share detailed information about its platform, the medical and investment communities will be watching closely for data supporting the technology's ability to overcome the immune clearance barrier that has limited previous virotherapy approaches. Success in this area could have significant implications for cancer treatment, potentially opening new avenues for combination therapies and personalized medicine approaches in immuno-oncology.
